ReviewCurrent opinion in endocrinology, diabetes, and obesity2009
Molecular markers of aggressiveness of thyroid cancer.
Review in Current opinion in endocrinology, diabetes, and obesity, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01384669 (Genetic Expression Alteration Affect on Lateral Neck Node Metastasis of Thyroid Papillary Microcarcinoma), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genetic Expression Alteration Affect on Lateral Neck Node Metastasis of Thyroid Papillary Microcarcinoma : Microarray Analysis
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Comparison of Clinical and Pathological Characteristics of Thyroid Cancer Surgery in the Pandemic Era.Medical journal of the Islamic Republic of Iran · 2024Article
- Extracellular Vesicles as Signal Carriers in Malignant Thyroid Tumors?International journal of molecular sciences · 2022Article
- New Insights into the Link between Melanoma and Thyroid Cancer: Role of Nucleocytoplasmic Trafficking.Cells · 2021Review
- Molecular Heterogeneity of Papillary Thyroid Cancer: Comparison of Primary Tumors and Synchronous Metastases in Regional Lymph Nodes by Mass Spectrometry Imaging.Endocrine pathology · 2019Article
- Article
- PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome.EJNMMI research · 2019Article
- Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?International journal of molecular sciences · 2017Review
- BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.World journal of surgery · 2016Article
- BRAF activates and physically interacts with PAK to regulate cell motility.Endocrine-related cancer · 2014Article
- Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier.Thyroid : official journal of the American Thyroid Association · 2011Review
- Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.Endocrine-related cancer · 2010Article
- Identification of Risk Factors for Cause-specific Mortality in Advanced Papillary Thyroid Cancer and Construction of a Competing Risk Model: A SEER-Based Study.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purpose of reviewTo review recent progress at defining molecular markers that predict the biological behavior of thyroid cancer. RECENT
findingsThyroid cancer behavior is defined by the effects of the initiating oncogene as well as secondary events in tumor cells and the tumor microenvironment that are both genetic and epigenetic. Over the past several years, there has been intense focus on identifying molecular markers to better predict the aggressiveness of thyroid cancers and also to define therapeutic targets. The results of recent articles in this area of work are summarized with a focus of differentiated follicular-cell-derived forms of thyroid cancer. SUMMARY: Clinical staging predicts tumor behavior in many cases, but does not allow true 'personalization' of initial therapy or identify potential therapeutic targets for patients with progressive disease that does not respond to standard therapies. Recent data point to several new opportunities to refine thyroid cancer treatment based on molecular information. Several highlighted articles have begun to apply this information with clinical intent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.